2 registrations that name nattokinase as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
All 2 registrations
RecruitingNCT07229521
Effects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders.
No phase
Taipei Medical University
About 80 people
Started Mar 15, 2025
In plain words A study of nattokinase in people 18 and older, run by Taipei Medical University. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Metabolic Syndrome; Sleeping Disorders.
Over 18 years old
Meet the criteria of MetS: meet at least two of the following four items will be recognized as at risk of metabolic syndrome:
High blood pressure: Systolic blood pressure≧120mmHg or diastolic blood pressure≧80mmHg
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nattokinase; Placebo
Registered summary
Nattokinase has been confirmed by many experiments to have a thrombolytic effect, but there are currently very few studies on nattokinase's effect on gut microbiota, sleeping status, and age-related cognitive function. Therefore, this study intends to explore the effect of nattokinase on cardiovascular disease risk factors, intestinal microbiota, sleep status and cognitive function in patients with metabolic syndrome risk and sleep disorders. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT06183307
Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia
No phase
Universidade Federal Fluminense
About 48 people
Started Aug 3, 2024
In plain words A study of nattokinase in people 18 and older, run by Universidade Federal Fluminense. It plans to enroll about 48 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Cardiovascular Diseases; Dyslipidemias; Inflammation.
Both sexes;
Over 18 years of age;
Isolated increase in LDL-c (LDL-c ≥ 160 mg/dL);
Isolated increase in triglycerides (TG ≥ 150 mg/dL or ≥ 175 mg/dL, without fasting);
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nattokinase; Placebo
Registered summary
The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.